These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14521488)

  • 1. The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.
    Doig CJ; Laupland KB; Zygun DA; Manns BJ
    Expert Opin Pharmacother; 2003 Oct; 4(10):1789-99. PubMed ID: 14521488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa (activated) approved for treatment of severe sepsis.
    Poe K
    J Am Pharm Assoc (Wash); 2002; 42(3):520-2. PubMed ID: 12030642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
    Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
    Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management challenge with drotrecogin alfa (activated).
    Vanscoy GJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
    Morris PE; Light RB; Garber GE
    Am J Surg; 2002 Dec; 184(6A Suppl):S19-24. PubMed ID: 12521614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
    Frampton JE; Foster RH
    Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Severe sepsis treated with activated protein C].
    Frøyshov S; Jacobsen D; Bjertnaes L; Flaatten H
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):779-81. PubMed ID: 15039807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
    Rudis MI; Fish DN
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa (activated) for severe sepsis.
    Drug Ther Bull; 2006 Jan; 44(1):5-8. PubMed ID: 16425899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis.
    Durthaler JM; Ernst FR
    Am J Health Syst Pharm; 2006 Aug; 63(15):1453-60. PubMed ID: 16849712
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk-benefit analysis for drotrecogin alfa (activated).
    Schein RM; Kinasewitz GT
    Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
    Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
    Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
    Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
    J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.
    Eichacker PQ; Natanson C
    Crit Care Med; 2003 Jan; 31(1 Suppl):S94-6. PubMed ID: 12544982
    [No Abstract]   [Full Text] [Related]  

  • 16. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
    Maki DG
    Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
    [No Abstract]   [Full Text] [Related]  

  • 17. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 18. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
    Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
    Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC).
    Chalfin DB; Teres D; Rapoport J
    Crit Care Med; 2003 Jan; 31(1):306-8. PubMed ID: 12545034
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical trials in severe sepsis with drotrecogin alfa (activated).
    Laterre PF
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S5. PubMed ID: 18269692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.